SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-000879
Filing Date
2021-01-11
Accepted
2021-01-11 17:10:18
Documents
12
Period of Report
2021-01-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K kzr-8k_20210108.htm   iXBRL 8-K 43441
  Complete submission text file 0001564590-21-000879.txt   177608

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kzr-20210108.xsd EX-101.SCH 5793
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kzr-20210108_lab.xml EX-101.LAB 20220
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kzr-20210108_pre.xml EX-101.PRE 12097
5 EXTRACTED XBRL INSTANCE DOCUMENT kzr-8k_20210108_htm.xml XML 3685
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 21521542
SIC: 2834 Pharmaceutical Preparations